"On April 15, 2014, the Chinese Ministry of Commerce ("MOFCOM") approved the Merger.
On April 16, 2014, the Company and Avago were notified by the Committee on Foreign Investment in the United States ("CFIUS") that CFIUS' investigation of the Merger is complete and that there are no unresolved national security concerns with respect to the Merger.
Clearance of the Merger by CFIUS and approval of the Merger by MOFCOM were the last regulatory approvals required to complete the Merger.
Subject to satisfaction of certain customary closing conditions set forth in the Merger Agreement, LSI expects to consummate the Merger in early May, after which time the Company's common stock will be delisted from the NASDAQ Global Select Market."
Nonsense. The HFT are responsible for cents back and forth, not for the 2 bucks drop from the $18 level. It is the unending litigation expenses that hit the share price. Large expenses (the so called multi-billion dollars "settlements") were revealed just after the stock peaked at $18+. The share price will rise after these very large expenses end.
The problem is that the litigation expenses continue unabated. Eventually they will diminish but for time being they kill the stock. Also the housing market is weakening.
Granted that TRIB has now the Meritas® Troponin Point of Care test. "Patients presenting with chest pain can now be tested at the POC so that the attending physician can quickly and accurately diagnose the condition and act earlier by sending the patient for proper treatment or allowing them to go home with confidence. With the high sensitivity of the Meritas® cTnI test, false positives are significantly reduced. Only healthy patients are sent home – thus greatly reducing the risk of subsequent short term incidents at home for these patients. The high specificity of the Meritas® cTnI test, and far fewer false positives, translates to only admitting sick patients and thus focusing hospital resources where most needed - eliminating needless costs associated with testing and caring for otherwise healthy people that could have been sent home but weren’t due to the false positive test results. "
Does TRIB have specific patents covering that high sensitivity POC Troponin test? Note that TRIB has spent only about $20M on acquiring the test platform and developing it. What would prevent the large diagnostic companies from developing a competitive POC product in a couple of years or so?
Talwalkar killed the share price when he greatly overpaid for Agere and took over its pension liabilities. Over the years, he has enriched himself getting outsized salary and options. If he had not sold LSI to Avago the share price today would be around $8 and management would continue to rape the shareholders taking outsized stock compensation. Those who bought large amounts of LSI for $7 and below (like myself) are not taking it in the shorts. Knowing the history of LSI before and during Talwalkar reign, I'm greatly relieved that LSI is finally sold for $11.15.
The market has ignored the recent 'Buy' and 'Outperform' ratings. The stock has been range-bound between $5.5. and $6.1. The earnings this quarter are expected to be mediocre. Hopefully the outlook will be better. The CEO got plenty of $0 stock options. It is time to show real improvement. After about a year on the job, the grace period of the CEO is over.
As Oclaro continues to have restructuring expenses and continuing losses at least until early 2015, the cash on hand will be reduced to well below $100M ; hence the need for secured revolving credit. If the company fails to become profitable in 2015, it will either be sold on the cheap or it will be bankruptcy time for real...
Analysts at Wunderlich began coverage on shares of Extreme Networks (NASDAQ:EXTR) in a research report issued to clients and investors on . The firm set a “buy” rating and a $9.00 price target on the stock. Wunderlich’s target price indicates a potential upside of 55.17% from the stock’s previous close.
The analysts wrote, “We are initiating coverage of Extreme Networks, Inc. (EXTR) with a Buy rating and 12-month target price of $9.00. Since purchasing Enterasys, Extreme has gained scale and uniqueness as an enterprise-focused network supplier with both switching and wireless. Growth opportunities are emerging with upgrade cycles: higher caliber wireless with analytics and network access control (NAC), as well as Ethernet fabrics for virtualization and lower latency. At approximately 1x the current revenue rate, valuation is attractive, in our opinion. “The investment risks involve integration challenges associated with a large acquisition that we believe are temporary. However, we view these risks to be more than justified by the prospects Extreme offers for investors to benefit from industry transition.”
Regarding the FDA, nothing influencing strongly the stock will happen before late this year. As the company said on March 4: "A pre-IDE meeting has been set up with the FDA – will be set up with the FDA as soon as possible, to discuss the scope of the U.S. trials and assuming that they are no surprises coming out of that discussion, the U.S. trials will be get underway in June of this year with FDA submission expected in September."
Everyone who is investing or following this stock has seen and read Raymond James' outperform rating for EXTR. The market seemed to ignore this rating. IMO, the reason for it is the poor outlook given in the last earnings report which was in contrast to the high expectations encouraged by the new CEO just a month before the earnings release. Also, EXTR has been releasing PRs but most of them are not about actual sales. The grace period for the new CEO is about over and the company will have to prove that it can actually grow and earn more than few cents a quarter. The old Extreme and Enterasys were stagnant. The combined companies have potential but the last earnings report shaded some doubts about it.
"Harmonic's financial have always been solid"
Over the years, Harmonic has made most of its income by issuing secondaries at prices above the current share price. This is why Harmonic's financials have been "solid". Other than that, actual profits per share have been sporadic and small especially accounting for goodwill amortization and stock based compensation. For the stockholders, Harmonic's promise as a long term investment has failed repeatedly. For example, as I recall, years back upon the acquisition of Omneon you expected a share price in the high teens within a couple of years following that acquisition. As I have said here before, the BOD needs to replace the CEO because he has failed to raise the share price during his 8 years tenure, a time of great advances in video. Something is wrong in the culture of Harmonic, a culture of underachievement. This is why it is desirable to have an outsider to lead this company into prosperity or a takeover.
C can not fix in 30 days the various deficiencies that the Fed claims it has. It will take a year or so. It can resubmit in 30 days a reduced capital plan but the stockholders will not be happy with it. It will take few quarters for the stock to recover from today's Fed action and the recent disappointing quarterly results. This stock really tortures its investors.
When a stock is richly priced (based on its actual results), a downward trend commences once the upward trend stalls. There is nothing unusual about it. Normally stocks go faster downward than upward. We are down about 17% from the recent peak about 3 weeks ago.
5 cents quarterly dividends are nothing for a $17 stock. The same apply for the measly $4B buybacks for a stock with $182B market cap. Meanwhile, BAC has to pay the FHFA $9.3B. All in all, these are not "great" news.
The following is the average EPS Trends of 3 analysts. Not much of a revision downward. The current Stock price is rich if one really believes that TRIB will earn only $1.16 in 2015. Assuming the new products take hold, TRIB should earn over $1.5 in 2015.
Mar 14 Jun 14 Current Year Dec 14 Next Year Dec 15
Current Estimate 0.19 0.21 0.88 1.16
7 Days Ago 0.19 0.21 0.88 1.16
30 Days Ago 0.20 0.22 0.94 1.17
60 Days Ago 0.22 0.23 0.96 1.18
90 Days Ago 0.22 0.23 0.96 1.18
Trinity Biotech plc (TRIB) saw a big move last session, as the company’s shares fell by over 7% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading below the volatile price range of $25.61 to $27.81 in the past one-month time frame.
This slump shouldn’t be too much of a surprise to investors, as the company has seen 1 negative revisions in the past few weeks and its current year earnings consensus has moved lower over the last 30 days. This suggests there may be more trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent slump will continue, as the earnings picture definitely suggests that this might be the case.
TRIB currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.
The recent earnings report did not exceed expectations and continued to show mid single-digit organic growth. The share price has been elevated because of perceived future prospects from the new products under development. The bullish sentiment has been very high so typically when the upward price momentum stalls, traders take profit expecting to reenter at lower price points. The very small dividend is essentially immaterial to the current price level. The company's cash level is now too low for it to support the stock price by buybacks.
1. Downgraded to Neutral, not to Sell.
2. Atlantic Equities's opinion regarding BAC is only one of many diverse opinions. It matters very little.
"March 17, 2014
05:57 EDT BHI Baker Hughes upgraded to Buy from Neutral at Goldman
Goldman upgraded Baker Hughes based on increased forecasts for pressure pumping and expected margin improvement. Price target raised to $72 from $60."
Often, Goldman's announced actions are contra indicators.